Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 5/20 | 0.35 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 2/20 | 0.34 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.34 |
| ▸ | TTK | P33981 | 4/20 | 0.34 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.33 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | CFTR | P13569 | 2/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22122854 | 1.00 | SYK (0.35) | SYKMAPKAPK5AXLPTK6TTK | |
| SCHEMBL30177732 | 0.97 | TTK (0.36) | SYKMAPKAPK5AXLPTK6TTK | |
| SCHEMBL22123307 | 0.97 | TTK (0.36) | SYKMAPKAPK5AXLPTK6TTK | |
| SCHEMBL30171950 | 0.97 | SYK (0.36) | SYKMAPKAPK5AXLPTK6TTK | |
| SCHEMBL22123399 | 0.97 | SYK (0.36) | SYKMAPKAPK5AXLPTK6TTK | |
| SCHEMBL22123019 | 0.96 | TTK (0.36) | SYKMAPKAPK5AXLPTK6TTK | |
| SCHEMBL30171885 | 0.96 | TTK (0.36) | SYKMAPKAPK5AXLPTK6TTK | |
| SCHEMBL22122926 | 0.96 | SYK (0.38) | SYKMAPKAPK5AXLPTK6TTK | |
| SCHEMBL22124546 | 0.95 | SYK (0.36) | SYKMAPKAPK5AXLPTK6TTK | |
| SCHEMBL30349860 | 0.95 | SYK (0.36) | SYKMAPKAPK5AXLPTK6TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | SYK 992/4885MAPKAPK5 728/4885AXL 2962/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | SYK 939/4885MAPKAPK5 695/4885AXL 3117/4885 |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IL4, RPS4Y1, RPS4X | SYK 868/4885MAPKAPK5 516/4885AXL 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.